Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
基本信息
- 批准号:9288927
- 负责人:
- 金额:$ 37.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2022-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntiviral AgentsBiologyCellsCellular MembraneDataEbola virusFibroblastsGoalsHemagglutininHumanHydrophobicityImageIn VitroIncomeInfectionInfection preventionInfluenzaIntegral Membrane ProteinInterferonsKnock-outKnockout MiceKnowledgeLinkLipidsLysosomesMeasuresMediatingMembraneMembrane FluidityMembrane FusionModificationMolecularMusPTEN genePathway interactionsPeptidesPhosphoric Monoester HydrolasesPost-Translational RegulationPredispositionProcessProteinsRegulationRegulatory PathwayReporterReportingResistanceResistance to infectionRoleSeveritiesShapesTestingTransmembrane DomainTumor Suppressor ProteinsVesicleVesicular stomatitis Indiana virusViralVirusVirus DiseasesWorkantiviral immunitybasecell typedesignfight againstfluorescence imagingin vivoinfluenzavirusmacrophagemouse modelnovelpathogenpreventubiquitin-protein ligase
项目摘要
PROJECT SUMMARY
Human cells possess many intrinsic mechanisms that provide resistance to incoming virus infections,
and a better understanding of these natural processes would be valuable in our ongoing fight against existing
and emergent viral diseases. The interferon-induced transmembrane proteins (IFITMs) are cellular factors that
potently block the fusion of multiple viruses. They are present in cells at steady state and also accumulate to
higher, more effective levels during infection. IFITM3 in particular reduces the severity of influenza virus
infections in both mice and humans. However, we currently lack a mechanistic understanding of how IFITM3
prevents influenza virus fusion. Likewise, we do not fully understand the regulatory processes controlling the
abundance of IFITM3 in cells. We seek to bridge these fundamental gaps in our knowledge with two specific
aims that will bring us closer to our long-term goal of designing IFITM3-based antivirals. Aim 1 will determine
the molecular mechanism by which IFITM3 alters cellular membranes to prevent virus fusion. We have newly
identified a short amphipathic helix within IFITM3 that we show is required for antiviral activity. Given that
amphipathic helices are well characterized to induce membrane curvature, we will determine the ability of this
helix to associate with and alter membranes, and will define its role in inhibiting influenza and other viruses.
This work will provide the first evidence for an amphipathicity-based mechanism of action for the IFITMs. Aim
2 is based on our discoveries that the steady state level of IFITM3 in cells is conversely negatively regulated by
the E3 ubiquitin ligase NEDD4 and positively regulated by the tumor suppressor PTEN. We have previously
shown that NEDD4 directly ubiquitinates IFITM3, targeting it for degradation in lysosomes. We will now
interrogate the mechanism by which PTEN promotes IFITM3 levels and resistance to influenza virus infection.
We will examine which enzymatic activity of PTEN is involved in regulating IFITM3, we will determine whether
PTEN and NEDD4 are involved in the same regulatory circuit, and finally, we will examine the involvement of
PTEN in IFITM3-mediated resistance to infection in vivo using newly generated mouse models. Overall, these
two independent aims will reveal complementary mechanisms that control IFITM3 activity and cellular
abundance.
项目总结
人类细胞拥有许多对即将到来的病毒感染提供抵抗力的内在机制,
更好地理解这些自然过程将对我们正在进行的对抗现有的
以及新出现的病毒性疾病。干扰素诱导的跨膜蛋白(IFITM)是一种细胞因子,
有效地阻止多种病毒的融合。它们以稳定状态存在于细胞中,并积累到
在感染期间,更高、更有效的水平。IFITM3尤其能降低流感病毒的严重程度
在老鼠和人类中都有感染。然而,我们目前缺乏对IFITM3的机械性理解
防止流感病毒融合。同样,我们也不完全了解控制
细胞内IFITM3的丰度。我们试图通过两个具体的例子来弥合我们知识中的这些根本差距
这些目标将使我们更接近设计基于IFITM3的抗病毒药物的长期目标。目标一号将决定
IFITM3改变细胞膜以阻止病毒融合的分子机制。我们有新的
在IFITM3中发现了一个短的两亲性螺旋,我们证明了这是抗病毒活性所必需的。考虑到
两亲性螺旋具有很好的诱导膜弯曲的特性,我们将确定这一能力
螺旋与膜结合并改变膜,并将确定其在抑制流感和其他病毒方面的作用。
这项工作将为IFITMS以两亲性为基础的行动机制提供第一个证据。目标
2是基于我们的发现,细胞中IFITM3的稳定水平相反地受到
E3泛素连接酶NEDD4,并受肿瘤抑制基因PTEN正调控。我们之前已经
结果表明,NEDD4直接泛化IFITM3,靶向它在溶酶体中降解。我们现在就会
询问PTEN促进IFITM3水平和对流感病毒感染的抵抗力的机制。
我们将研究PTEN的哪些酶活性参与调节IFITM3,我们将确定
PTEN和NEDD4参与相同的调节回路,最后,我们将研究参与
PTEN在IFITM3介导的新生小鼠体内感染抵抗中的作用。总的来说,这些
两个独立的目标将揭示控制IFITM3活性和细胞的互补机制
富足。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacob Yount其他文献
Jacob Yount的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacob Yount', 18)}}的其他基金
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10597869 - 财政年份:2023
- 资助金额:
$ 37.7万 - 项目类别:
Establishing a relevant mouse model with susceptibility to non-adapted influenza viruses for vaccine challenge studies
建立对非适应性流感病毒易感的相关小鼠模型,用于疫苗攻击研究
- 批准号:
10211108 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10531244 - 财政年份:2017
- 资助金额:
$ 37.7万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10367235 - 财政年份:2017
- 资助金额:
$ 37.7万 - 项目类别:
Mechanisms of innate resistance to virus infections
对病毒感染的先天抵抗机制
- 批准号:
10084253 - 财政年份:2017
- 资助金额:
$ 37.7万 - 项目类别:
Molecular Control of IFITM3 in Restricting Influenza Virus Infection
IFITM3 在限制流感病毒感染中的分子控制
- 批准号:
9012283 - 财政年份:2015
- 资助金额:
$ 37.7万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8165228 - 财政年份:2011
- 资助金额:
$ 37.7万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应器的机制分析
- 批准号:
8601556 - 财政年份:2011
- 资助金额:
$ 37.7万 - 项目类别:
Mechanistic analysis of a posttranslationally modified innate antiviral effector
翻译后修饰的先天抗病毒效应子的机制分析
- 批准号:
8623095 - 财政年份:2011
- 资助金额:
$ 37.7万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 37.7万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 37.7万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 37.7万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 37.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 37.7万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 37.7万 - 项目类别: